Fostamatinib disodium (R935788)
Drug100 mg tablet, orally, twice-a-day
Other names: R935788
Completed
NCT Number: NCT00665925
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) inhibitor, R935788 (R788), at a dose of 100 mg, orally, twice-a-day, and/or a dose of of 150 mg, orally, once-a-day is effective in the treatment of Rheumatoid Arthrits in patients who have had an inadequate clinical response to methotrexate.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
MNTranspH "Tsar Boris Treti", Sofia, Gsof, Bulgaria
Loading trial locations.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients must give written informed consent by signing an IRB/EC-approved Informed Consent Form (ICF) prior to admission to this study.
- Males and females, 18 years of age or older, with active RA for at least 6 months prior to Day 1 dosing.
- Patients must have been receiving weekly methotrexate doses (7.5-25 mg/week) for a minimum of 3 months prior to Day 1 dosing and must be receiving a stable MTX dose, with no change in route, for the previous 6 weeks prior to Day 1 dosing.
'Patients must be receiving a folic or folinic acid supplementation at a stable dose for at least 6 weeks prior to Day 1 dosing.
- Females of childbearing potential must be fully informed of the potential for R788 to adversely affect the fetus and, if sexually active, must agree to use a well established method of birth control during the study (oral contraceptive, mechanical barrier, long acting hormonal agent). These patients must not be lactating and must have a negative urine pregnancy test at the time of randomization and at each laboratory determination.
- The patient must otherwise be in good health as determined by the Investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period. See exclusion criteria for specific exclusions.
- In the Investigator's opinion, the patient has the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol.
Exclusion criteria
- The patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the Investigator's opinion, could affect the conduct of the study. Specifically, excluded are patients with the following:
- uncontrolled or poorly controlled hypertension;
- other autoimmune disease (psoriatic arthritis, lupus, mixed connective disorder) or arthritis syndromes (gout, Lyme disease, Reiter's syndrome);
- recent (within past 2 months prior to Day 1 dosing) serious surgery or infectious disease;
- recent history (past 5 years prior to Day 1 dosing) of, or treatment for, a malignancy other than nonmelanomatous skin cancer, or any history of lymphoma;
- Hepatitis B ;
- Hepatitis C ;
- interstitial pneumonitis or active pulmonary infection on chest x-ray;
- Tuberculosis (TB): the TB skin test should be negative.
- known laboratory abnormalities.
- The patient has a history of substance abuse, drug addiction or alcoholism. Patients may consume up to 4 units of alcohol per week; however, alcohol should be avoided in the 72 hours prior to lab assessments. Patients who cannot reliably comply with this should be excluded. A unit of alcohol is defined as the following: Beer=12 oz or 355 mL; wine = 5 oz or 148 mL; sweet dessert wine=3 oz or 89 mL; 80 proof distilled spirits= 1.5 oz or 44 mL.
- The patient has been treated previously treated with R788 under a different protocol.
Treatment and study plan
Placebo
DrugPlacebo, orally, either once a day, or twice a day
Primary outcomes
-
American College of Rheumatology 20 (ACR20) Response at 6 Months
Time frame: 6 months
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 6 months
Secondary outcomes
-
American College of Rheumatology 20 (ACR20) Response at 1 Week
Time frame: 1 week
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 1 week
-
American College of Rheumatology 20 (ACR20) Response at 2 Weeks
Time frame: 2 weeks
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 2 weeks
-
American College of Rheumatology 20 (ACR20) Response at 1 Month
Time frame: 1 month
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 1 month
-
American College of Rheumatology 20 (ACR20) Response at 6 Weeks
Time frame: 6 weeks
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 6 weeks
-
American College of Rheumatology 20 (ACR20) Response at 2 Months
Time frame: 2 months
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 2 months
-
American College of Rheumatology 20 (ACR20) Response at 3 Months
Time frame: 3 months
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 3 months
-
American College of Rheumatology 20 (ACR20) Response at 4 Months
Time frame: 4 months
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 4 months
-
American College of Rheumatology 20 (ACR20) Response at 5 Months
Time frame: 5 months
The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 5 months
-
American College of Rheumatology 50 (ACR50) Response at 1 Week
Time frame: 1 week
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 1 week
-
American College of Rheumatology 50 (ACR50) Response at 2 Weeks
Time frame: 2 weeks
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 2 weeks
-
American College of Rheumatology 50 (ACR50) Response at 1 Month
Time frame: 1 month
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 1 month
-
American College of Rheumatology 50 (ACR50) Response at 6 Weeks
Time frame: 6 weeks
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 6 weeks
-
American College of Rheumatology 50 (ACR50) Response at 2 Months
Time frame: 2 months
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 2 months
-
American College of Rheumatology 50 (ACR50) Response at 3 Months
Time frame: 3 months
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 3 months
-
American College of Rheumatology 50 (ACR50) Response at 4 Months
Time frame: 4 months
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 4 months
-
American College of Rheumatology 50 (ACR50) Response at 5 Months
Time frame: 5 months
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 5 months
-
American College of Rheumatology 50 (ACR50) Response at 6 Months
Time frame: 6 months
The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 6 months
-
American College of Rheumatology 70 (ACR70) Response at 1 Week
Time frame: 1 week
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 1 week
-
American College of Rheumatology 70 (ACR70) Response at 2 Weeks
Time frame: 2 weeks
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 2 weeks
-
American College of Rheumatology 70 (ACR70) Response at 1 Month
Time frame: 1 month
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 1 month
-
American College of Rheumatology 70 (ACR70) Response at 6 Weeks
Time frame: 6 weeks
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 6 weeks
-
American College of Rheumatology 70 (ACR70) Response at 2 Months
Time frame: 2 months
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 2 months
-
American College of Rheumatology 70 (ACR70) Response at 3 Months
Time frame: 3 months
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 3 months
-
American College of Rheumatology 70 (ACR70) Response at 4 Months
Time frame: 4 months
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 4 months
-
American College of Rheumatology 70 (ACR70) Response at 5 Months
Time frame: 5 months
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 5 months
-
American College of Rheumatology 70 (ACR70) Response at 6 Months
Time frame: 6 months
The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR), after 6 months
-
American College of Rheumatology Index of Improvement (ACRn) at 1 Week
Time frame: 1 week
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 1 week of treatment
-
American College of Rheumatology Index of Improvement (ACRn) at 2 Weeks
Time frame: 2 weeks
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 2 weeks of treatment
-
American College of Rheumatology Index of Improvement (ACRn) at 1 Month
Time frame: 1 month
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 1 month of treatment
-
American College of Rheumatology Index of Improvement (ACRn) at 6 Weeks
Time frame: 6 weeks
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 6 weeks of treatment
-
American College of Rheumatology Index of Improvement (ACRn) at 2 Months
Time frame: 2 months
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 2 months of treatment
-
American College of Rheumatology Index of Improvement (ACRn) at 3 Months
Time frame: 3 months
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 3 months of treatment
-
American College of Rheumatology Index of Improvement (ACRn) at 4 Months
Time frame: 4 months
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 4 months of treatment
-
American College of Rheumatology Index of Improvement (ACRn) at 5 Months
Time frame: 5 months
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 5 months of treatment
-
American College of Rheumatology Index of Improvement (ACRn) at 6 Months
Time frame: 6 months
The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 6 months of treatment
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 1 Month
Time frame: 1 month
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 2 Months
Time frame: 2 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 3 Months
Time frame: 3 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 4 Months
Time frame: 4 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 5 Months
Time frame: 5 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 6 Months
Time frame: 6 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 1 Month
Time frame: 1 month
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 2 Months
Time frame: 2 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 3 Months
Time frame: 3 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 4 Months
Time frame: 4 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 5 Months
Time frame: 5 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 6 Months
Time frame: 6 months
Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 1 Month
Time frame: 1 month
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 2 Months
Time frame: 2 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 3 Months
Time frame: 3 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 4 Months
Time frame: 4 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 5 Months
Time frame: 5 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 6 Months
Time frame: 6 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 1 Month
Time frame: 1 month
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 2 Months
Time frame: 2 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 3 Months
Time frame: 3 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 4 Months
Time frame: 4 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 5 Months
Time frame: 5 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 6 Months
Time frame: 6 months
Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity
-
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at 6 Months
Time frame: Baseline to 6 months
Change from baseline in FACIT-F, which is a patient-reported 13-item questionnaire that assesses fatigue, calculated as the score at 6 months minus the score at baseline. The FACIT-F runs from 0 to 52 with lower scores indicating higher fatigue. A positive change from baseline indicates an improvement in fatigue after treatment.
-
Short Form Health Survey (SF-36) Physical Component Summary (PCS) at 6 Months
Time frame: Baseline to 6 months
Change from baseline in the PCS of the SF-36 (which assesses health and wellbeing), calculated as the score at 6 months minus the score at baseline. The PCS ranges from 0 to 100 with 100 indicating the highest level of functioning possible. A positive change indicates an improvement in PCS after treatment
-
Short Form Health Survey (SF-36) Mental Component Summary (MCS) at 6 Months
Time frame: Baseline to 6 months
Change from baseline in the MCS of the SF-36 (which assesses health and wellbeing), calculated as the score at 6 months minus the score at baseline. The MCS ranges from 0 to 100 with 100 indicating the highest level of functioning possible. A positive change indicates an improvement in MCS after treatment
-
Alanine Aminotransferase (ALT) >1.5x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with ALT (a test of liver function) values greater than 1.5 times the ULN
-
Alanine Aminotransferase (ALT) >1.5-2x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with ALT (a test of liver function) values greater than 1.5 to 2 times the ULN
-
Alanine Aminotransferase (ALT) >2-3x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with ALT (a test of liver function) values greater than 2 to 3 times the ULN
-
Alanine Aminotransferase (ALT) >3x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with ALT (a test of liver function) values greater than 3 times the ULN
-
Alanine Aminotransferase (ALT) >3-5x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with ALT (a test of liver function) values greater than 3 to 5 times the ULN
-
Alanine Aminotransferase (ALT) >5-10x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with ALT (a test of liver function) values greater than 5 to 10 times the ULN
-
Alanine Aminotransferase (ALT) >10x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with ALT (a test of liver function) values greater than 10 times the ULN
-
Aspartate Aminotransferase (AST) >1.5x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with AST (a test of liver function) values greater than 1.5 times the ULN
-
Aspartate Aminotransferase (AST) >1.5-2x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with AST (a test of liver function) values greater than 1.5-2 times the ULN
-
Aspartate Aminotransferase (AST) >2-3x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with AST (a test of liver function) values greater than 2 to 3 times the ULN
-
Aspartate Aminotransferase (AST) >3x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with AST (a test of liver function) values greater than 3 times the ULN
-
Aspartate Aminotransferase (AST) >3-5x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with AST (a test of liver function) values greater than 3 to 5 times the ULN
-
Aspartate Aminotransferase (AST) >5-10 x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with AST (a test of liver function) values greater than 5 to 10 times the ULN
-
Aspartate Aminotransferase (AST) >10 x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with AST (a test of liver function) values greater than 10 times the ULN
-
Alkaline Phosphatase >1.5 x Upper Limit of Normal (ULN) and >1.5 Times Baseline
Time frame: Any time between baseline and 6 months
The number of participants with alkaline phosphatase (a test of liver function) values greater than 1.5 times the ULN and greater than 1.5 times baseline
-
Bilirubin >1.5 x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with bilirubin (a test of liver function) values greater than 1.5 times the ULN
-
Bilirubin >2 x Upper Limit of Normal (ULN)
Time frame: Any time between baseline and 6 months
The number of participants with bilirubin (a test of liver function) values greater than 2 times the ULN
-
Absolute Neutrophil Count (ANC) <1500/mm3
Time frame: Any time between baseline and 6 months
The number of participants with ANC (a test of liver function) values lower than 1500/mm3
Sponsors and collaborators
Lead sponsor
Rigel Pharmaceuticals
Industry
Registry information
Official study title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate
Acronym: Taski-2
Important dates
- Study start
- 2008
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Apr 24, 2008
- Registry last updated
- Sep 16, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
Dietary Salt in Rheumatoid Arthritis
NCT03649178
Arthritis, Arthritis, Rheumatoid
Nashville, Tennessee, United States
View Trial Details
Completed
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
NCT03025308
Arthritis, Arthritis, Rheumatoid
Huntsville, Alabama, United States
View Trial Details
Completed
Umbilical Cord Mesenchymal Stromal Cell Secretome for Moderate Rheumatoid Arthritis: A Randomized Double-Blind Placebo-Controlled Trial
NCT07715045
Arthritis, Arthritis, Rheumatoid
Palembang, South Sumatera, Indonesia
View Trial Details
Completed
Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
NCT00055055
Arthritis, Arthritis, Rheumatoid
Bethesda, Maryland, United States
View Trial Details